# 510(k) SUBSTANTIAL EQUIVALENCE DETERMINATION DECISION SUMMARY

A. 510(k) Number: K080380   
B. Purpose for Submission: New device, combining the immunoassay test strips from the individual SAS™ Influenza A and SAS™ Influenza B Tests into one side-by-side plastic cassette   
C. Measurand: Influenza A and influenza B viral nucleoprotein antigens Influenza types detected: influenza A and influenza B   
D. Type of Test: A rapid immunoassay for the qualitative detection of influenza A and influenza B viral nucleoprotein in nasal washes and nasal aspirates   
E. Applicant: SA Scientific, Ltd.   
F. Proprietary and Established Names: SAS™ FluAlert A & B Test   
G. Regulatory Information:

<table><tr><td>Product Code</td><td>Classification</td><td>Regulation Section</td><td>Panel</td></tr><tr><td>GNX</td><td>Class II</td><td>21 CFR 866.3330 Antigens, Cf (including Cf controls) influenza virus A, B, C</td><td>Microbiology (83)</td></tr></table>

# H. Intended Use:

1. Intended use(s):

SAS™ FluAlert A & B Test is a visual and rapid assay for the presumptive in-vitro qualitative detection of influenza A and influenza B viral nucleoprotein antigens from nasal washes and nasal aspirates of symptomatic patients. The test is not intended for the detection of Influenza Type C viral antigen. This test is for professional use only.

Negative results do not preclude infection with influenza A or B and should not be used as the sole basis for treatment or other patient management decisions. It is recommended that negative results be confirmed by cell culture.

2. Indication(s) for use: Same as Intended Use

3. Special conditions for use statement(s): For prescription use only

4. Special instrument requirements: N/A

# I. Device Description:

The SAS™ FluAlert A & B Test is an immunoassay comprised of two strips in one cassette. One strip utilizing monoclonal antibodies against influenza type A nucleoproteins and the second strip utilizing influenza type B viral nucleoproteins. In the presence of influenza A and/or influenza B, the antibodygold conjugate in the test membranes binds to the nucleoproteins and forms a complex. This complex migrates across the membrane and is captured by influenza A or influenza B antibodies in the membrane and forms visible pink lines. To serve as a procedural control, a pink line will always appear in the control zone of each strip regardless of the presence or absence of influenza A or influenza B nucleoproteins.

# J. Substantial Equivalence Information:

1. Predicate device name(s): SAS™ Influenza A Test (K044141) and SAS™ Influenza B Test (K041439), manufactured by SA Scientific, Ltd., San Antonio, TX.

2. Predicate K number(s): K044141 K041439

3. Comparison with predicate:

<table><tr><td colspan="4" rowspan="1">Similarities</td></tr><tr><td colspan="1" rowspan="1">Item</td><td colspan="1" rowspan="1">Device</td><td colspan="1" rowspan="1">Predicate 1</td><td colspan="1" rowspan="1">Predicate 2</td></tr><tr><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">The SASTM FluAlert A &amp;B Test</td><td colspan="1" rowspan="1">SASTM Influenza ATest (K044141)</td><td colspan="1" rowspan="1">SASTM Influenza BTest (K041439)</td></tr><tr><td colspan="1" rowspan="1">Technology</td><td colspan="1" rowspan="1">Immunoassay</td><td colspan="1" rowspan="1">Immunoassay</td><td colspan="1" rowspan="1">Immunoassay</td></tr><tr><td colspan="1" rowspan="1">OrganismDetected</td><td colspan="1" rowspan="1">Influenza A and B</td><td colspan="1" rowspan="1">Influenza A</td><td colspan="1" rowspan="1">Influenza B</td></tr><tr><td colspan="1" rowspan="1">Intended Use</td><td colspan="1" rowspan="1">Detection of influenza Aand B viralnucleoproteins</td><td colspan="1" rowspan="1">Detection ofinfluenza A viralnucleoproteins</td><td colspan="1" rowspan="1">Detection of influenzaB viral nucleoproteins</td></tr><tr><td colspan="4" rowspan="1">Differences</td></tr><tr><td colspan="1" rowspan="1">Item</td><td colspan="1" rowspan="1">Device</td><td colspan="1" rowspan="1">Predicate 1</td><td colspan="1" rowspan="1">Predicate 2</td></tr><tr><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">The SASTM FluAlert A&amp; B Test</td><td colspan="1" rowspan="1">SASTM Influenza ATest (K044141)</td><td colspan="1" rowspan="1">SASTM Influenza BTest (K041439)</td></tr><tr><td colspan="1" rowspan="1">DeviceConfiguration</td><td colspan="1" rowspan="1">Two strips in a cassettefor detection of influenzaA and influenza B</td><td colspan="1" rowspan="1">One strip in a cassettefor detection ofinfluenza A</td><td colspan="1" rowspan="1">One strip in a cassettefor detection ofinfluenza B</td></tr></table>

# K. Standard/Guidance Documents Referenced (if applicable):

Guidance on In Vitro Diagnostic Devices to Detect Influenza A Viruses: Labeling and Regulatory Path - http://www.fda.gov/cdrh/oivd/guidance/1594.pdf.

# L. Test Principle:

The $\mathrm { S A S ^ { T M } }$ FluAlert A & B Test utilizes monoclonal antibodies against influenza Type A and influenza Type B viral nucleoproteins. The test begins with an extraction of nucleoproteins from the clinical specimen. The extracted specimen is then placed into two separate sample wells and observed for the formation of colored lines. The specimen is absorbed and migrates via capillary action through membranes that contain dried gold conjugated antibody specific for either influenza A or influenza B nucleoproteins. If Type A and/or Type B nucleoproteins are present, they bind to the antibody-gold conjugate and form a complex which migrates across the membrane and is captured by influenza A or influenza B antibodies in the membrane. Thus, in the presence of influenza A and influenza B nucleoproteins, an immuno-complex is formed and a visible pink line develops in the specimen zones of the test device, in the A line for influenza A and in the B line for influenza B. In the absence of influenza A and/or influenza B antigens, an immuno-complex is not formed and a negative result is indicated. To serve as a procedural control, a pink line should appear in the control zones regardless of the presence or absence of influenza A and influenza B nucleoproteins.

# Interpretation of Results:

Expected Performance of Controls:

# Internal Controls

Each test device includes an internal procedural control, a line in the C (control) regions of the test device. Correct procedural technique, specimen flow and test device performance is confirmed when a colored line appears in the C areas of the membrane. If the colored line fails to appear in the C area of either strip, the test result is invalid.

A clear background is an internal negative procedural control. The background color should be white to light pink and should not interfere with the reading of the test result. If a more intensely red background color appears, it may

interfere with the ability to read the test result, therefore the test should be repeated.

# External Controls

Negative and Positive controls for influenza A antigen and influenza B antigen should be tested and the appropriate results obtained. External quality control testing should be performed in conformance with local, state and federal regulations or accreditation organizations as applicable, and should follow the user’s laboratory’s standard quality control procedures. Controls in the SAS™ FluAlert Control Kit, catalog # 046230, are ready to use; do not dilute with extraction buffer.

# Specimen Results and Interpretation:

• The test is negative if a colored line appears only in the C (control) area on both strips.   
• The test is positive for Flu A if the line appears under S (specimen) on the Flu A strip and a second line appears under the C on both strips. The test is positive for Flu B if the line appears under S on the Flu B strip and a second line appears under C on both strips. Any pink colored line in the specimen (S) area, regardless of the intensity, is a positive result.   
• While co-infections with both influenza A and influenza B viruses are rare and no incidences were observed in the clinical studies, they might occur. If there is a question about the test results, the test may be repeated.   
• The test is invalid if no colored line appears in the C area on either strip, even if a colored line appears in either S area. If this occurs, the test should be repeated.

# M. Performance Characteristics (if/when applicable):

1. Analytical Performance:

a. Precision/Reproducibility:

The reproducibility of the $\mathbf { S } \mathbf { A } \mathbf { S } ^ { \mathbf { T M } }$ FluAlert A&B Test was evaluated at three clinical sites. Three or four non-professional users per site tested the SAS™ FluAlert A&B Test against a panel of approximately 30 aliquots each of six (6) panel members over a two-week period. Specimens were comprised of pooled nasal aspirates and included two (2) levels of positives for influenza A and two (2) for influenza B and one negative for each virus. The influenza A panel members contained H3N2 A/Hong Kong/8/68 and the influenza B panel members contained B/Allen/45. Negative specimens for influenza A and influenza B were in concentrations below the limit of detection.

Reproducibility Study Summary for the SAS™ FluAlert A & B Test   

<table><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>PanelMember</td><td rowspan=1 colspan=1>InfluenzaA  HighNegative</td><td rowspan=1 colspan=1>InfluenzaA LowPositive</td><td rowspan=1 colspan=1>Influenza AModeratePositive</td><td rowspan=1 colspan=1>Influenza BHighNegative</td><td rowspan=1 colspan=1>InfluenzaB LowPositive</td><td rowspan=1 colspan=1>InfluenzaBModeratePositive</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>Viral TiterFinal Conc.TCID50/0.2 ml</td><td rowspan=1 colspan=1>1.8 x 103</td><td rowspan=1 colspan=1>7 x 103</td><td rowspan=1 colspan=1>1.4 x 104</td><td rowspan=1 colspan=1>2.8 x 102</td><td rowspan=1 colspan=1>1.1 x 103</td><td rowspan=1 colspan=1>2.2 x 103</td></tr><tr><td rowspan=3 colspan=1>Agree-mentwithExpectedResult</td><td rowspan=1 colspan=1>Site 1</td><td rowspan=1 colspan=1>29 Neg/3096.7%</td><td rowspan=1 colspan=1>26 Pos/3086.6%</td><td rowspan=1 colspan=1>29 Pos/3096.7%</td><td rowspan=1 colspan=1>28 Neg/2996.6%</td><td rowspan=1 colspan=1>29 Pos/3096.7%</td><td rowspan=1 colspan=1>29 Pos/29100%</td></tr><tr><td rowspan=1 colspan=1>Site 2</td><td rowspan=1 colspan=1>29 Neg/3096.7%</td><td rowspan=1 colspan=1>26 Pos/2989.7%</td><td rowspan=1 colspan=1>29 Pos/29100%</td><td rowspan=1 colspan=1>30 Neg/30100%</td><td rowspan=1 colspan=1>29 Pos/3096.7%</td><td rowspan=1 colspan=1>30 Pos/30100%</td></tr><tr><td rowspan=1 colspan=1>Site 3</td><td rowspan=1 colspan=1>28 Neg/3093.3%</td><td rowspan=1 colspan=1>27 Pos/3090.0%</td><td rowspan=1 colspan=1>30 Pos/30100%</td><td rowspan=1 colspan=1>26 Neg/2989.7%</td><td rowspan=1 colspan=1>29 Pos/3096.7%</td><td rowspan=1 colspan=1>30 Pos/30100%</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>TotalAgreement</td><td rowspan=1 colspan=1>95.6%</td><td rowspan=1 colspan=1>88.8%</td><td rowspan=1 colspan=1>98.9%</td><td rowspan=1 colspan=1>95.4%</td><td rowspan=1 colspan=1>96.7%</td><td rowspan=1 colspan=1>100%</td></tr></table>

$b$ . Linearity/assay reportable range: Not applicable, qualitative assay   
c. Traceability, Stability, Expected values (controls, calibrators, or methods): N/A

# d. Detection limit:

The Limit of Detection (LoD) for the $\mathbf { S A S ^ { T M } }$ FluAlert A&B Test was determined using quantified $\mathrm { ( T C I D _ { 5 0 } / m l ) }$ cultures of five (5) each Influenza A and Influenza B viral strains received from the ATCC. Each strain was serially diluted in $\mathbf { S A S ^ { T M } }$ FluAlert extraction buffer. Strains were assayed using the $\mathbf { S A S ^ { T M } }$ FluAlert A&B Test until no positive signal could be seen. LoD was calculated to determine the lowest detectable concentration range of influenza.

Limit of Detection Summary   

<table><tr><td rowspan=1 colspan=1>InfluenzaViral Strain</td><td rowspan=1 colspan=1>ATCC</td><td rowspan=1 colspan=1>LoDTCID50/0.2 ml</td></tr><tr><td rowspan=1 colspan=1>H1N1 A/PR/3/34</td><td rowspan=1 colspan=1>VR-95</td><td rowspan=1 colspan=1>1.2 x 105</td></tr><tr><td rowspan=1 colspan=1>H3N2A/Aichi/2/68</td><td rowspan=1 colspan=1>VR-547</td><td rowspan=1 colspan=1>5.6 x 102</td></tr><tr><td rowspan=1 colspan=1>H3N2A/HongKong/8/6/8</td><td rowspan=1 colspan=1>VR-544</td><td rowspan=1 colspan=1>3.5 x 103</td></tr><tr><td rowspan=1 colspan=1>H1N1A/FM/147</td><td rowspan=1 colspan=1>VR-97</td><td rowspan=1 colspan=1>7.9 x 103</td></tr><tr><td rowspan=1 colspan=1>H3N2A/Victoria/3/75</td><td rowspan=1 colspan=1>VR-822</td><td rowspan=1 colspan=1>4.5 x 105</td></tr><tr><td rowspan=1 colspan=1>InfluenzaB/Lee/40</td><td rowspan=1 colspan=1>VR-101</td><td rowspan=1 colspan=1>9.9 x 104</td></tr><tr><td rowspan=1 colspan=1>InfluenzaB/Allen/45</td><td rowspan=1 colspan=1>VR-102</td><td rowspan=1 colspan=1>5.6 x 102</td></tr><tr><td rowspan=1 colspan=1>InfluenzaB/Mass/3/66</td><td rowspan=1 colspan=1>VR-523</td><td rowspan=1 colspan=1>4.5 x 102</td></tr><tr><td rowspan=1 colspan=1>InfluenzaB/Taiwan/2/62</td><td rowspan=1 colspan=1>VR-295</td><td rowspan=1 colspan=1>3.5 x 101</td></tr><tr><td rowspan=1 colspan=1>Influenza B/Maryland/1/59</td><td rowspan=1 colspan=1>VR-296</td><td rowspan=1 colspan=1>1.6 x 102</td></tr></table>

e. Analytical specificity:

Analytical specificity of the SAS™ FluAlert A&B Test was evaluated for potential cross-reactivity and interference with non-influenza pathogens associated with respiratory tract infections.

# Cross-Reactivity Evaluation

Twenty-two virus strains were obtained from ATCC or other commercial sources. Each cultured viral strain was tested on the $\mathrm { S A S ^ { T M } }$ FluAlert A&B Test at concentrations listed in the table below.

Cross-reactivity Test Results with Common Viral Respiratory Pathogens   

<table><tr><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">Ctrvley Test R</td><td></td><td colspan="1" rowspan="1">i Respl atol y 1 a</td><td colspan="1" rowspan="1"></td></tr><tr><td colspan="1" rowspan="1">Virus</td><td colspan="1" rowspan="1">ATTC/Lot #</td><td colspan="1" rowspan="1">Concentration</td><td colspan="1" rowspan="1">"A" portion ofthe SASTMFluAlert A&amp;B</td><td colspan="1" rowspan="1">"B" portionof the SASTMFluAlertA&amp;B</td></tr><tr><td colspan="1" rowspan="1">Adenovirus 5</td><td colspan="1" rowspan="1">10-198-000</td><td colspan="1" rowspan="1">1.2 x 1010 TCID50 /0.2 ml</td><td colspan="1" rowspan="1">Neg</td><td colspan="1" rowspan="1">Neg</td></tr><tr><td colspan="1" rowspan="1">Adenovirus 7</td><td colspan="1" rowspan="1">VR7</td><td colspan="1" rowspan="1">3.2 x 103 TCID50 /0.2 ml</td><td colspan="1" rowspan="1">Neg</td><td colspan="1" rowspan="1">Neg</td></tr><tr><td colspan="1" rowspan="1">Adenovirus 10</td><td colspan="1" rowspan="1">VR1087</td><td colspan="1" rowspan="1">3.2 x 10³ TCID50 /0.2 ml</td><td colspan="1" rowspan="1">Neg</td><td colspan="1" rowspan="1">Neg</td></tr><tr><td colspan="1" rowspan="1">CoxsackieA9</td><td colspan="1" rowspan="1">VR186</td><td colspan="1" rowspan="1">3.2 x 102 TCID50 /0.2 ml</td><td colspan="1" rowspan="1">Neg</td><td colspan="1" rowspan="1">Neg</td></tr><tr><td colspan="1" rowspan="1">CoxsackieB5</td><td colspan="1" rowspan="1">VR185</td><td colspan="1" rowspan="1">3.2 x 106 TCID50 /0.2 ml</td><td colspan="1" rowspan="1">Neg</td><td colspan="1" rowspan="1">Neg</td></tr><tr><td colspan="1" rowspan="1">Cytomegalovirus</td><td colspan="1" rowspan="1">021301</td><td colspan="1" rowspan="1">20 μg/ml</td><td colspan="1" rowspan="1">Neg</td><td colspan="1" rowspan="1">Neg</td></tr><tr><td colspan="1" rowspan="1">Echovirus11</td><td colspan="1" rowspan="1">VR1052</td><td colspan="1" rowspan="1">NA</td><td colspan="1" rowspan="1">Neg</td><td colspan="1" rowspan="1">Neg</td></tr><tr><td colspan="1" rowspan="1">Echovirus3</td><td colspan="1" rowspan="1">VR1040</td><td colspan="1" rowspan="1">1 x 104 TCID50 /0.2 ml</td><td colspan="1" rowspan="1">Neg</td><td colspan="1" rowspan="1">Neg</td></tr><tr><td colspan="1" rowspan="1">Echovirus 6</td><td colspan="1" rowspan="1">VR1044</td><td colspan="1" rowspan="1">3.2 x 106 TCID50 /0.2 ml</td><td colspan="1" rowspan="1">Neg</td><td colspan="1" rowspan="1">Neg</td></tr><tr><td colspan="1" rowspan="1">HSV-1</td><td colspan="1" rowspan="1">2J30000</td><td colspan="1" rowspan="1">15 μg/ml</td><td colspan="1" rowspan="1">Neg</td><td colspan="1" rowspan="1">Neg</td></tr><tr><td colspan="1" rowspan="1">HSV-2</td><td colspan="1" rowspan="1">8J29502</td><td colspan="1" rowspan="1">15 μg/ml</td><td colspan="1" rowspan="1">Neg</td><td colspan="1" rowspan="1">Neg</td></tr><tr><td colspan="1" rowspan="1">Varicella zoster</td><td colspan="1" rowspan="1">1102097</td><td colspan="1" rowspan="1">12 μg/ml</td><td colspan="1" rowspan="1">Neg</td><td colspan="1" rowspan="1">Neg</td></tr><tr><td colspan="1" rowspan="1">Parainfluenza 1</td><td colspan="1" rowspan="1">VR907</td><td colspan="1" rowspan="1">5.6 x 106 TCID50 /0.2 ml</td><td colspan="1" rowspan="1">Neg</td><td colspan="1" rowspan="1">Neg</td></tr><tr><td colspan="1" rowspan="1">Parainfluenza 2</td><td colspan="1" rowspan="1">VR92</td><td colspan="1" rowspan="1">1.8 x 105 TCID50 /0.2 ml</td><td colspan="1" rowspan="1">Neg</td><td colspan="1" rowspan="1">Neg</td></tr><tr><td colspan="1" rowspan="1">Parainfluenza 3</td><td colspan="1" rowspan="1">VR93</td><td colspan="1" rowspan="1">3.2 x 106 TCID50 /0.2 ml</td><td colspan="1" rowspan="1">Neg</td><td colspan="1" rowspan="1">Neg</td></tr><tr><td colspan="1" rowspan="1">RSV Long</td><td colspan="1" rowspan="1">VR26</td><td colspan="1" rowspan="1">0.1 x 105.5 TCID50 /0.2 ml</td><td colspan="1" rowspan="1">Neg</td><td colspan="1" rowspan="1">Neg</td></tr><tr><td colspan="1" rowspan="1">RSV B</td><td colspan="1" rowspan="1">VR1400</td><td colspan="1" rowspan="1">0.1 x 105.25TCID50 /0.2ml</td><td colspan="1" rowspan="1">Neg</td><td colspan="1" rowspan="1">Neg</td></tr><tr><td colspan="1" rowspan="1">Influenza BAllen</td><td colspan="1" rowspan="1">VR102</td><td colspan="1" rowspan="1">3.2 x 103 TCID50 /0.2 ml</td><td colspan="1" rowspan="1">Neg</td><td colspan="1" rowspan="1">X</td></tr><tr><td colspan="1" rowspan="1">Influenza B Lee</td><td colspan="1" rowspan="1">VR101</td><td colspan="1" rowspan="1">3.2 x 106 TCID50 /0.2 ml</td><td colspan="1" rowspan="1">Neg</td><td colspan="1" rowspan="1"></td></tr><tr><td colspan="1" rowspan="1">Influenza B Mass</td><td colspan="1" rowspan="1">VR523</td><td colspan="1" rowspan="1">1.8 x 103 TCID50 /0.2 ml</td><td colspan="1" rowspan="1">Neg</td><td colspan="1" rowspan="1"></td></tr><tr><td colspan="1" rowspan="1">Influenza BMaryland</td><td colspan="1" rowspan="1">VR296</td><td colspan="1" rowspan="1">1 x 104 TCID50 /0.2 ml</td><td colspan="1" rowspan="1">Neg</td><td colspan="1" rowspan="1">X</td></tr><tr><td colspan="1" rowspan="1">Influenza BTaiwan</td><td colspan="1" rowspan="1">VR295</td><td colspan="1" rowspan="1">5.6 x 102 TCID50 /0.2 ml</td><td colspan="1" rowspan="1">Neg</td><td colspan="1" rowspan="1">X</td></tr><tr><td colspan="1" rowspan="1">Influenza A(H1N1) PR</td><td colspan="1" rowspan="1">VR95</td><td colspan="1" rowspan="1">1.8 x 104 TCID50 /0.2 ml</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">Neg</td></tr><tr><td colspan="1" rowspan="1">Influenza A(H3N2) Aichci</td><td colspan="1" rowspan="1">VR547</td><td colspan="1" rowspan="1">1.8 x 106 TCID50 /0.2 ml</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">Neg</td></tr><tr><td colspan="1" rowspan="1">Influenza A</td><td colspan="1" rowspan="1">VR544</td><td colspan="1" rowspan="1">5.6 x 104 TCID50 /0.2 ml</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">Neg</td></tr><tr><td colspan="1" rowspan="1">(H3N2) HongKong</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td></tr><tr><td colspan="1" rowspan="1">Influenza A FM</td><td colspan="1" rowspan="1">VR97</td><td colspan="1" rowspan="1">3.2 x 104 TCID50 /0.2 ml</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">Neg</td></tr><tr><td colspan="1" rowspan="1">Influenza A(H3N2) Victoria</td><td colspan="1" rowspan="1">VR822</td><td colspan="1" rowspan="1">1.8 x 106 TCID50 /0.2 ml</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">Neg</td></tr></table>

One yeast and fourteen bacterial strains were obtained from ATCC or other commercial sources. Each cultured bacterial or yeast strain was diluted to a concentration of $\mathrm { 1 x 1 0 ^ { 8 } c f u / m l }$ and tested on the $\mathbf { S A S ^ { T M } }$ FluAlert A&B Test.

Cross-reactivity Test Results with Common Bacterial Respiratory Pathogens   

<table><tr><td rowspan=1 colspan=1>Bacteria or Yeast</td><td rowspan=1 colspan=1>&quot;A&quot; portion ofthe SASTMFluAlert A&amp;B</td><td rowspan=1 colspan=1>&quot;B&quot; portion ofthe SASTMFluAlert A&amp;B</td></tr><tr><td rowspan=1 colspan=1>Candida albicans</td><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>Neg</td></tr><tr><td rowspan=1 colspan=1>Chlamydia trachomatis</td><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>Neg</td></tr><tr><td rowspan=1 colspan=1>Corynebacterium diphtheriae</td><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>Neg</td></tr><tr><td rowspan=1 colspan=1>Haemophilus influenza</td><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>Neg</td></tr><tr><td rowspan=1 colspan=1>Klebsiella pneumoniae</td><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>Neg</td></tr><tr><td rowspan=1 colspan=1>Serratia marcescens</td><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>Neg</td></tr><tr><td rowspan=1 colspan=1>Staphylococcus epidermidis</td><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>Neg</td></tr><tr><td rowspan=1 colspan=1>Staphylococcus aureus</td><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>Neg</td></tr><tr><td rowspan=1 colspan=1>Streptococcus sp gr A</td><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>Neg</td></tr><tr><td rowspan=1 colspan=1>Streptococcus sp gr F</td><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>Neg</td></tr><tr><td rowspan=1 colspan=1>Streptococcus sp gr G</td><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>Neg</td></tr><tr><td rowspan=1 colspan=1>Streptococcus pneumoniae</td><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>Neg</td></tr><tr><td rowspan=1 colspan=1>Mycoplasma pneumoniae</td><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>Neg</td></tr><tr><td rowspan=1 colspan=1>Neisseria meningitidis</td><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>Neg</td></tr><tr><td rowspan=1 colspan=1>Pseudomonas aeruginosa</td><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>Neg</td></tr></table>

The study demonstrated that the $\mathbf { S A S ^ { T M } }$ FluAlert A&B Test did not crossreact with any respiratory pathogens or commensal organisms tested. The data demonstrated $100 \%$ concordance with the expected results.

# Interference Study

The analytical specificity of the influenza A portion of the SAS™ FluAlert A&B was evaluated by testing a panel of 22 viruses, 14 bacteria, and one yeast species which may be found in the respiratory tract. For the influenza A portion of the test, influenza whole virus strain A/FM/147 (ATCC VR97) at a titer of $7 . 9 \mathrm { \times 1 0 ^ { 3 } T C I D } _ { 5 0 } / 0 . 2 \mathrm { m l }$ was added to viral cultures and viral antigens at the concentrations listed in the table below and bacterial and yeast cultures at concentrations of $1 \mathrm { { x } 1 0 ^ { 8 } c f u / m l }$ . For the influenza B portion of the test, whole virus strain B/Mass/3/66 (ATCC VR523) at a titer of $3 . 2 \mathrm { ~ x ~ } 1 0 ^ { 3 } \mathrm { T C I D } _ { 5 0 } / 0 . 2 \mathrm { m l }$ . was added to viral cultures in the concentrations listed in the table below and bacterial and yeast cultures at $1 \mathrm { ~ x ~ } 1 0 ^ { 8 }$ cfu/ml.

# SAS™ FluAlert A&B Interference Test Results

<table><tr><td rowspan=1 colspan=1>Virus</td><td rowspan=1 colspan=1>ATTC/Lot#</td><td rowspan=1 colspan=1>Concentration</td><td rowspan=1 colspan=1>&quot;A&quot; Portionof the SASTMFluAlertA&amp;B</td><td rowspan=1 colspan=1>&quot;B&quot; Portionof theSASTMFluAlertA&amp;B</td></tr><tr><td rowspan=1 colspan=1>Adenovirus 5</td><td rowspan=1 colspan=1>10-198-000</td><td rowspan=1 colspan=1>1.2 x 1010 TCID50 /0.2 ml</td><td rowspan=1 colspan=1>Pos</td><td rowspan=1 colspan=1>Pos</td></tr><tr><td rowspan=1 colspan=1>Adenovirus 7</td><td rowspan=1 colspan=1>VR7</td><td rowspan=1 colspan=1>3.2 x 103 TCID50 /0.2 ml</td><td rowspan=1 colspan=1>Pos</td><td rowspan=1 colspan=1>Pos</td></tr><tr><td rowspan=1 colspan=1>Adenovirus 10</td><td rowspan=1 colspan=1>VR1087</td><td rowspan=1 colspan=1>3.2 x 103 TCID50 /0.2 ml</td><td rowspan=1 colspan=1>Pos</td><td rowspan=1 colspan=1>Pos</td></tr><tr><td rowspan=1 colspan=1>CoxsackieA9</td><td rowspan=1 colspan=1>VR186</td><td rowspan=1 colspan=1>3.2 x 102 TCID50 /0.2 ml</td><td rowspan=1 colspan=1>Pos</td><td rowspan=1 colspan=1>Pos</td></tr><tr><td rowspan=1 colspan=1>CoxsackieB5</td><td rowspan=1 colspan=1>VR185</td><td rowspan=1 colspan=1>3.2 x 106 TCID50 /0.2 ml</td><td rowspan=1 colspan=1>Pos</td><td rowspan=1 colspan=1>Pos</td></tr><tr><td rowspan=1 colspan=1>Cytomegalovirus</td><td rowspan=1 colspan=1>021301</td><td rowspan=1 colspan=1>20 μg/ml</td><td rowspan=1 colspan=1>Pos</td><td rowspan=1 colspan=1>Pos</td></tr><tr><td rowspan=1 colspan=1>Echovirus11</td><td rowspan=1 colspan=1>VR1052</td><td rowspan=1 colspan=1>NA</td><td rowspan=1 colspan=1>Pos</td><td rowspan=1 colspan=1>Pos</td></tr><tr><td rowspan=1 colspan=1>Echovirus3</td><td rowspan=1 colspan=1>VR1040</td><td rowspan=1 colspan=1>1 x 104 TCID50 /0.2 ml</td><td rowspan=1 colspan=1>Pos</td><td rowspan=1 colspan=1>Pos</td></tr><tr><td rowspan=1 colspan=1>Echovirus6</td><td rowspan=1 colspan=1>VR1044</td><td rowspan=1 colspan=1>3.2 x 106 TCID50 /0.2 ml</td><td rowspan=1 colspan=1>Pos</td><td rowspan=1 colspan=1>Pos</td></tr><tr><td rowspan=1 colspan=1>HSV-1</td><td rowspan=1 colspan=1>2J30000</td><td rowspan=1 colspan=1>15 μg/ml</td><td rowspan=1 colspan=1>Pos</td><td rowspan=1 colspan=1>Pos</td></tr><tr><td rowspan=1 colspan=1>HSV-2</td><td rowspan=1 colspan=1>8J29502</td><td rowspan=1 colspan=1>15 μg/ml</td><td rowspan=1 colspan=1>Pos</td><td rowspan=1 colspan=1>Pos</td></tr><tr><td rowspan=1 colspan=1>Varicella zoster</td><td rowspan=1 colspan=1>1102097</td><td rowspan=1 colspan=1>12 μg/ml</td><td rowspan=1 colspan=1>Pos</td><td rowspan=1 colspan=1>Pos</td></tr><tr><td rowspan=1 colspan=1>Parainfluenza 1</td><td rowspan=1 colspan=1>VR907</td><td rowspan=1 colspan=1>5.6 x 106 TCID50 /0.2 ml</td><td rowspan=1 colspan=1>Pos</td><td rowspan=1 colspan=1>Pos</td></tr><tr><td rowspan=1 colspan=1>Parainfluenza 2</td><td rowspan=1 colspan=1>VR92</td><td rowspan=1 colspan=1>1.8 x 105 TCID50 /0.2 ml</td><td rowspan=1 colspan=1>Pos</td><td rowspan=1 colspan=1>Pos</td></tr><tr><td rowspan=1 colspan=1>Parainfluenza 3</td><td rowspan=1 colspan=1>VR93</td><td rowspan=1 colspan=1>3.2 x 106 TCID50 /0.2 ml</td><td rowspan=1 colspan=1>Pos</td><td rowspan=1 colspan=1>Pos</td></tr><tr><td rowspan=1 colspan=1>RSV Long</td><td rowspan=1 colspan=1>VR26</td><td rowspan=1 colspan=1>0.1 x 105.5 TCID50 /0.2 ml</td><td rowspan=1 colspan=1>Pos</td><td rowspan=1 colspan=1>Pos</td></tr><tr><td rowspan=1 colspan=1>RSV B</td><td rowspan=1 colspan=1>VR1400</td><td rowspan=1 colspan=1>0.1 x 105.25 TCID50 /0.2 ml</td><td rowspan=1 colspan=1>Pos</td><td rowspan=1 colspan=1>Pos</td></tr><tr><td rowspan=1 colspan=1>Influenza B Allen</td><td rowspan=1 colspan=1>VR102</td><td rowspan=1 colspan=1>3.2 x 103 TCID50 /0.2 ml</td><td rowspan=1 colspan=1>Pos</td><td rowspan=1 colspan=1></td></tr><tr><td rowspan=1 colspan=1>Influenza B Lee</td><td rowspan=1 colspan=1>VR101</td><td rowspan=1 colspan=1>3.2 x 106 TCID50 /0.2 ml</td><td rowspan=1 colspan=1>Pos</td><td rowspan=1 colspan=1></td></tr><tr><td rowspan=1 colspan=1>Influenza B Mass</td><td rowspan=1 colspan=1>VR523</td><td rowspan=1 colspan=1>1.8 x 103 TCID50 /0.2 ml</td><td rowspan=1 colspan=1>Pos</td><td rowspan=1 colspan=1></td></tr><tr><td rowspan=1 colspan=1>Influenza B Maryland</td><td rowspan=1 colspan=1>VR296</td><td rowspan=1 colspan=1>1 x 104 TCID50 /0.2 ml</td><td rowspan=1 colspan=1>Pos</td><td rowspan=1 colspan=1></td></tr><tr><td rowspan=1 colspan=1>Influenza B Taiwan</td><td rowspan=1 colspan=1>VR295</td><td rowspan=1 colspan=1>5.6 x 102 TCID50 /0.2 ml</td><td rowspan=1 colspan=1>Pos</td><td rowspan=1 colspan=1></td></tr><tr><td rowspan=1 colspan=1>Influenza A (H1N1)PR</td><td rowspan=1 colspan=1>VR95</td><td rowspan=1 colspan=1>1.8 x 104 TCID50 /0.2 ml</td><td rowspan=1 colspan=1>X</td><td rowspan=1 colspan=1>Pos</td></tr><tr><td rowspan=1 colspan=1>Influenza A (H3N2)Aichci</td><td rowspan=1 colspan=1>VR547</td><td rowspan=1 colspan=1>1.8 x 106 TCID50 /0.2 ml</td><td rowspan=1 colspan=1>X</td><td rowspan=1 colspan=1>Pos</td></tr><tr><td rowspan=1 colspan=1>Influenza A (H3N2)Hong Kong</td><td rowspan=1 colspan=1>VR544</td><td rowspan=1 colspan=1>5.6 x 104 TCID50 /0.2 ml</td><td rowspan=1 colspan=1>X</td><td rowspan=1 colspan=1>Pos</td></tr><tr><td rowspan=1 colspan=1>Influenza A FM</td><td rowspan=1 colspan=1>VR97</td><td rowspan=1 colspan=1>3.2 x 104 TCID50 /0.2 ml</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>Pos</td></tr><tr><td rowspan=1 colspan=1>Influenza A (H3N2)Victoria</td><td rowspan=1 colspan=1>VR822</td><td rowspan=1 colspan=1>1.8 x 106 TCID50 /0.2 ml</td><td rowspan=1 colspan=1>X</td><td rowspan=1 colspan=1>Pos</td></tr></table>

One yeast and fourteen bacterial strains were obtained from ATCC or other commercial sources. Each cultured bacterial or yeast strain was diluted to a concentration of $\mathrm { { 1 x 1 0 ^ { 8 } \ c f u / m l } }$ and tested on the $\mathbf { S A S ^ { T M } }$ FluAlert A&B Test.

# SAS™ FluAlert A&B Interference Test Results

<table><tr><td rowspan=1 colspan=1>Bacteria or Yeast</td><td rowspan=1 colspan=1>&quot;A&quot; portion ofthe SASTMFluAlert A&amp;B</td><td rowspan=1 colspan=1>&quot;B&quot; portion ofthe SASTMFluAlert A&amp;B</td></tr><tr><td rowspan=1 colspan=1>Candida albicans</td><td rowspan=1 colspan=1>Pos</td><td rowspan=1 colspan=1>Pos</td></tr><tr><td rowspan=1 colspan=1>Chlamydia trachomatis</td><td rowspan=1 colspan=1>Pos</td><td rowspan=1 colspan=1>Pos</td></tr><tr><td rowspan=1 colspan=1>Corynebacterium diphtheriae</td><td rowspan=1 colspan=1>Pos</td><td rowspan=1 colspan=1>Pos</td></tr><tr><td rowspan=1 colspan=1>Haemophilus influenza</td><td rowspan=1 colspan=1>Pos</td><td rowspan=1 colspan=1>Pos</td></tr><tr><td rowspan=1 colspan=1>Klebsiella pneumoniae</td><td rowspan=1 colspan=1>Pos</td><td rowspan=1 colspan=1>Pos</td></tr><tr><td rowspan=1 colspan=1>Serratia marcescens</td><td rowspan=1 colspan=1>Pos</td><td rowspan=1 colspan=1>Pos</td></tr><tr><td rowspan=1 colspan=1>Staphylococcus epidermidis</td><td rowspan=1 colspan=1>Pos</td><td rowspan=1 colspan=1>Pos</td></tr><tr><td rowspan=1 colspan=1>Staphylococcus aureus</td><td rowspan=1 colspan=1>Pos</td><td rowspan=1 colspan=1>Pos</td></tr><tr><td rowspan=1 colspan=1>Streptococcus sp gr A</td><td rowspan=1 colspan=1>Pos</td><td rowspan=1 colspan=1>Pos</td></tr><tr><td rowspan=1 colspan=1>Streptococcus sp gr F</td><td rowspan=1 colspan=1>Pos</td><td rowspan=1 colspan=1>Pos</td></tr><tr><td rowspan=1 colspan=1>Streptococcus sp gr G</td><td rowspan=1 colspan=1>Pos</td><td rowspan=1 colspan=1>Pos</td></tr><tr><td rowspan=1 colspan=1>Streptococcus pneumoniae</td><td rowspan=1 colspan=1>Pos</td><td rowspan=1 colspan=1>Pos</td></tr><tr><td rowspan=1 colspan=1>Mycoplasma pneumoniae</td><td rowspan=1 colspan=1>Pos</td><td rowspan=1 colspan=1>Pos</td></tr><tr><td rowspan=1 colspan=1>Neisseria meningitidis</td><td rowspan=1 colspan=1>Pos</td><td rowspan=1 colspan=1>Pos</td></tr><tr><td rowspan=1 colspan=1>Pseudomonas aeruginosa</td><td rowspan=1 colspan=1>Pos</td><td rowspan=1 colspan=1>Pos</td></tr></table>

f. Assay cut-off:

N/A

2. Comparison studies: a. Method comparison with predicate device:

# Prospective Clinical Study

The SAS™ FluAlert A&B Test combines the immunoassay test strips from the individual $\mathbf { S } \mathbf { A } \mathbf { S } ^ { \mathbf { T M } }$ Influenza A and SAS™ Influenza B Tests into one side-by-side plastic cassette. There are no other changes made to this test. In these studies, the users compared the combined test to the individual tests for evaluation of user interpretations. Please see: “Results Summary: SAS™ Influenza A and $\mathrm { S A S ^ { T M } }$ Influenza B Individual Devices compared to cell culture or DFA” chart for comparison of the individual tests to cell culture/DFA.

Four clinical trial sites, in Texas and South Dakota, tested four hundred sixty one (461) nasal clinical specimens blindly and prospectively comparing the SAS™ Influenza A Test and The SAS™ FluAlert A&B (combined) Test performance. The $\mathrm { S A S ^ { T M } }$ Influenza A Test and $\mathbf { S } \mathbf { A } \mathbf { S } ^ { \mathbf { T M } }$ FluAlert A&B Test had a positive percent agreement of $9 7 . 2 \%$ and a negative percent agreement of $9 9 . 7 \%$ . Thirteen samples yielded invalid results. .

Four clinical trial sites, in Texas and South Dakota, tested four hundred sixty one (461) nasal clinical specimens blindly and prospectively comparing the SAS™ Influenza B Test and the SAS™ FluAlert A&B (combined) Test performance. The SAS™ Influenza B test and SAS™ FluAlert A&B Test had a positive percent agreement of $9 8 . 7 \%$ and a negative percent agreement of $9 9 . 7 \%$ .

Clinical sites collected the nasal wash samples during the 2007-2008 and 2008 – 2009 influenza seasons from an approximately equal mix of adult $( > 2 1$ years) and pediatric patients (0-21 years). The nasal aspirate samples were collected predominately from pediatric patients.

Demographics of fresh specimens:   

<table><tr><td rowspan=1 colspan=1>Age (years)</td><td rowspan=1 colspan=1>Number ofNasal Washspecimens</td><td rowspan=1 colspan=1>% ofTotal NWSpecimens</td><td rowspan=1 colspan=1>Number ofNasal AspirateSpecimens</td><td rowspan=1 colspan=1>% ofTotal NASpecimens</td></tr><tr><td rowspan=1 colspan=1>0-5</td><td rowspan=1 colspan=1>16</td><td rowspan=1 colspan=1>5.7%</td><td rowspan=1 colspan=1>73</td><td rowspan=1 colspan=1>40.1%</td></tr><tr><td rowspan=1 colspan=1>6-21</td><td rowspan=1 colspan=1>21</td><td rowspan=1 colspan=1>7.5%</td><td rowspan=1 colspan=1>108</td><td rowspan=1 colspan=1>59.3%</td></tr><tr><td rowspan=1 colspan=1>22 - 65</td><td rowspan=1 colspan=1>25</td><td rowspan=1 colspan=1>9.0%</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>0.6%</td></tr><tr><td rowspan=1 colspan=1>&gt;65</td><td rowspan=1 colspan=1>9</td><td rowspan=1 colspan=1>3.2%</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1></td></tr><tr><td rowspan=1 colspan=1>Not Determined</td><td rowspan=1 colspan=1>208</td><td rowspan=1 colspan=1>74.5%</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1></td></tr><tr><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=1>279</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>182</td><td rowspan=1 colspan=1></td></tr></table>

# Fresh, Prospective Nasal Aspirates:

Influenza A Comparison Results

SAS™ Influenza A Test   

<table><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>+</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td></tr><tr><td rowspan=1 colspan=1>+</td><td rowspan=1 colspan=1>44</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>44</td></tr><tr><td rowspan=1 colspan=1>-</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>137</td><td rowspan=1 colspan=1>138</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>45</td><td rowspan=1 colspan=1>137</td><td rowspan=1 colspan=1>182</td></tr></table>

SAS™ FluAlert A & B Combined Test Total

Positive $\%$ Agreement: $9 7 . 8 \%$ ( $9 5 \%$ CI 87-100%) Negative $\%$ Agreement: $1 0 0 \%$ $9 7 \%$ CI 95-100%)

Influenza B Comparison Results

SAS™ Influenza B Test   

<table><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>+</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td></tr><tr><td rowspan=1 colspan=1>+</td><td rowspan=1 colspan=1>37</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>37</td></tr><tr><td rowspan=1 colspan=1>-</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>145</td><td rowspan=1 colspan=1>145</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>37</td><td rowspan=1 colspan=1>145</td><td rowspan=1 colspan=1>182</td></tr></table>

SAS™ FluAlert A & B Combined Test Total

Positive $\%$ Agreement: $1 0 0 \%$ $9 5 \%$ CI 97-100%) Negative $\%$ Agreement: $1 0 0 \%$ $9 5 \%$ CI 88-100%)

# Fresh, Prospective Nasal Washes:

Influenza A Comparison Results

SAS™ FluAlert A & B Combined Test Total

SAS™ Influenza A Test   

<table><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>+</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td></tr><tr><td rowspan=1 colspan=1>+</td><td rowspan=1 colspan=1>26</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>27</td></tr><tr><td rowspan=1 colspan=1>-</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>251</td><td rowspan=1 colspan=1>252</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>27</td><td rowspan=1 colspan=1>252</td><td rowspan=1 colspan=1>279</td></tr></table>

Positive $\%$ Agreement: $9 6 . 3 \%$ ( $9 5 \%$ CI 79-100%) Negative $\%$ Agreement: $9 9 . 6 \%$ $9 5 \% \mathbf { C I 9 7 - 1 0 0 \% }$

Influenza B Comparison Results

SAS™ FluAlert A & B Combined Test Total

SAS™ Influenza B Test   

<table><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>+</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td></tr><tr><td rowspan=1 colspan=1>+</td><td rowspan=1 colspan=1>40</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>41</td></tr><tr><td rowspan=1 colspan=1>-</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>237</td><td rowspan=1 colspan=1>238</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>41</td><td rowspan=1 colspan=1>238</td><td rowspan=1 colspan=1>279</td></tr></table>

Positive $\%$ Agreement: $9 7 . 6 \%$ $( 9 5 \% \mathrm { C I } 8 6  – 1 0 0 \% )$ Negative $\%$ Agreement: $9 9 . 6 \%$ ( $9 5 \% \mathrm { C I } 9 7 – 1 0 0 \% )$

# Results Summary: Fresh Nasal Washes and Aspirates

Influenza A Comparison Results

SAS™ Influenza A Test

SAS™ FluAlert A & B Combined Test Total

<table><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>+</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td></tr><tr><td rowspan=1 colspan=1>+</td><td rowspan=1 colspan=1>70</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>71</td></tr><tr><td rowspan=1 colspan=1>-</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>388</td><td rowspan=1 colspan=1>390</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>72</td><td rowspan=1 colspan=1>389</td><td rowspan=1 colspan=1>461</td></tr></table>

Positive $\%$ Agreement: $9 7 . 2 \%$ ( $9 5 \%$ CI879-100%) Negative $\%$ Agreement: $9 9 . 7 \%$ $9 5 \%$ CI 98-100%)

Influenza B Comparison Results

SAS™ FluAlert A & B Combined Test Total

SAS™ Influenza B Test   

<table><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>+</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td></tr><tr><td rowspan=1 colspan=1>+</td><td rowspan=1 colspan=1>77</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>78</td></tr><tr><td rowspan=1 colspan=1>-</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>382</td><td rowspan=1 colspan=1>383</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>78</td><td rowspan=1 colspan=1>383</td><td rowspan=1 colspan=1>461</td></tr></table>

Positive $\%$ Agreement: $9 8 . 7 \%$ $\mathbf { ( 9 5 \% 6 7 1 9 2  – 1 0 0 \% ) }$ Negative $\%$ Agreement: $9 9 . 7 \%$ $9 5 \% \mathrm { C I } 9 8 – 1 0 0 \% )$

Note: Performance characteristics for detecting the 2009 H1N1 influenza virus from human specimens have not been established

# Retrospective Study

To supplement the prospective study, 191 frozen, archived, nasal wash samples from a children’s hospital in Texas were blindly assayed comparing the individual SAS™ Influenza A Test and the individual SAS™ Influenza B Test to the $\mathbf { S A S ^ { T M } }$ FluAlert A&B (combined) Test. For these samples, the positive percent agreement with the influenza A Test is $100 \%$ and negative percent agreement is $9 9 . 3 \%$ , while positive percent agreement with the Influenza B Test was $9 4 . 7 \%$ and negative percent agreement is $9 8 . 0 \%$

# SAS™ Influenza

# A Test

# SAS™ FluAlert A&B Combined Test

Total

<table><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>+</td><td rowspan=1 colspan=1>-</td><td rowspan=1 colspan=1></td></tr><tr><td rowspan=1 colspan=1>+</td><td rowspan=1 colspan=1>27</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>28</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>163</td><td rowspan=1 colspan=1>163</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>27</td><td rowspan=1 colspan=1>164</td><td rowspan=1 colspan=1>191</td></tr></table>

Positive $\%$ Agreement: $1 0 0 \%$ $9 5 \%$ CI 84-100%) Negative $\%$ Agreement: $9 9 . 3 \%$ ( $9 5 \%$ CI 96-100%)

SAS™ Influenza B Test   
SAS™ FluAlert A & B Combined Test Total   

<table><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>+</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td></tr><tr><td rowspan=1 colspan=1>+</td><td rowspan=1 colspan=1>36</td><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>39</td></tr><tr><td rowspan=1 colspan=1>-</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>150</td><td rowspan=1 colspan=1>152</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>38</td><td rowspan=1 colspan=1>153</td><td rowspan=1 colspan=1>191</td></tr></table>

Positive $\%$ Agreement: $9 4 . 7 \%$ $( 9 5 \% \mathrm { C I } 8 1 – 9 9 \% )$ Negative $\%$ Agreement: $9 8 . 0 \%$ ( $9 5 \%$ CI 94-99%)

b. Matrix comparison: Not applicable

3. Clinical studies:

a and b. Clinical Sensitivity and Specificity:

# SAS™ Influenza A and SAS™ Influenza B individual devices compared to cell culture or DFA.

The performance of the SAS™ Influenza A and SAS™ Influenza B individual devices was established during the 2002-2003 and 2003-2004 flu seasons, at clinical sites in Iowa, Virginia, and South Dakota. A total of 263 and 255 clinical specimens, respectively, were tested using the SAS Influenza A and Influenza B devices and the results were compared to cell culture or DFA. Specimens were comprised of leftover nasopharyngeal

washes, nasal washes and nasopharyngeal aspirates, and were tested blindly and prospectively. Results are shown in the following table.

<table><tr><td rowspan=1 colspan=2>All Specimens</td><td rowspan=1 colspan=3>SASTM Influenza A Test</td><td rowspan=1 colspan=3>SASTM Influenza B Test</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>+</td><td rowspan=1 colspan=1>-</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>+</td><td rowspan=1 colspan=1>-</td><td rowspan=1 colspan=1></td></tr><tr><td rowspan=2 colspan=1>CellCulture/DFA</td><td rowspan=1 colspan=1>+</td><td rowspan=1 colspan=1>57</td><td rowspan=1 colspan=1>4</td><td rowspan=1 colspan=1>61</td><td rowspan=1 colspan=1>19</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>19</td></tr><tr><td rowspan=1 colspan=1>-</td><td rowspan=1 colspan=1>18</td><td rowspan=1 colspan=1>184</td><td rowspan=1 colspan=1>202</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>234</td><td rowspan=1 colspan=1>236</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>75</td><td rowspan=1 colspan=1>188</td><td rowspan=1 colspan=1>263</td><td rowspan=1 colspan=1>21</td><td rowspan=1 colspan=1>234</td><td rowspan=1 colspan=1>255</td></tr><tr><td rowspan=1 colspan=1>Sensitivity95% CI</td><td rowspan=1 colspan=3>76%65-85%</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=3>90.5%68-98%</td></tr><tr><td rowspan=1 colspan=1>Specificity95% CI</td><td rowspan=1 colspan=3>97.9%94-99.%</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=3>100%98-100%</td></tr></table>

4. Clinical cut-off:

Not applicable

5. Expected values/Reference range:

Influenza prevalence varies year to year, with the highest number of cases in the fall and winter months in the US. During the period of September 30, 2007 to April 5, 2008, prevalence in the US for both influenza A and influenza B was $1 8 . 5 \%$ , with $74 \%$ of those cases attributed to influenza A and $2 6 \%$ attributed to influenza B. For studies conducted on the SAS™ FluAlert A&B Test, during the 2007-2008 and 2008-2009 seasons, prevalence for fresh, prospective nasal washes and nasal aspirates was $1 5 . 1 \%$ for influenza A and $1 6 . 5 \%$ for influenza B.

# N. Proposed Labeling:

The labeling is sufficient and it satisfies the requirements of 21 CFR Part 809.10.

# O. Conclusion:

The submitted information in this premarket notification is complete and supports a substantial equivalence decision.